The activation of cancer-promoting factor EGFR can up-regulate the expression of IL-6, JAK1/STAT3 signaling pathway and deteriorate NSCLC (non-small cell lung cancer), which was the reason for drug resistance. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.